Update on lipoprotein(a) as a cardiovascular risk factor and mediator topical collection on clinical trials and their interpretations

Current Atherosclerosis Reports

Volumn 15, Issue 10, 2013, Pages

  Boffa, Michael B ^a   Koschinsky, Marlys L ^a  

^a UNIVERSITY OF WINDSOR   (Canada)

Author keywords

Apolipoprotein(a); Atherosclerosis; Cardiovascular disease; Clinical chemistry; Coronary heart disease; Fibrinolysis; Genetics; Inflammation; LDL; Lipoprotein(a); Mendelian randomization; Niacin; Oxidized phospholipids; Risk factors; Thrombosis

Indexed keywords

APOLIPOPROTEIN; LIPOPROTEIN A;

ANIMAL; CARDIOVASCULAR DISEASES; GENETICS; HUMAN; METABOLISM; OXIDATION REDUCTION REACTION; RISK FACTOR; VASCULAR CALCIFICATION;

ANIMALS; APOLIPOPROTEINS; CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEIN(A); OXIDATION-REDUCTION; RISK FACTORS; VASCULAR CALCIFICATION;

EID: 84897366580     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-013-0360-6     Document Type: Article

References (92)

1. • Dubé JB, Boffa MB, Hegele RA, Koschinsky ML. Lipoprotein(a): more interesting than ever after 50 years. Curr Opin Lipidol. 2012;23:133-40. This is one of a quintet of recent reviews that together comprehensively survey the current landscape of Lp(a) research.
2. • Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. J Intern Med. 2013;273:6-30. This is one of a quintet of recent reviews that together comprehensively survey the current landscape of Lp(a) research.
3. • Taleb A, Witztum JL, Tsimikas S. Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomark Med. 2011;5:673-94. This is one of a quintet of recent reviews that together comprehensively survey the current landscape of Lp(a) research.
4. • Kolski B, Tsimikas S. Emerging therapeutic agents to lower lipoprotein (a) levels. Curr Opin Lipidol. 2012;23:560-68. This is one of a quintet of recent reviews that together comprehensively survey the current landscape of Lp(a) research.
5. Fless GM, Rolih CA, Scanu AM. Heterogeneity of human plasma lipoprotein (a). Isolation and characterization of the lipoprotein subspecies and their apoproteins. J Biol Chem. 1984;259:11470-8. (Pubitemid 14010034)
6. • Tsimikas S, Hall JL. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease. J Am Coll Cardiol. 2012;60:716-21. This is one of a quintet of recent reviews that together comprehensively survey the current landscape of Lp(a) research.
7. McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330:132-7. (Pubitemid 17158542)
8. Koschinsky ML. Novel insights into Lp(a) physiology and pathogenicity: more questions than answers? Cardiovasc Hematol Disord Drug Targets. 2006;6:267-78. (Pubitemid 44890588)
9. Gabel BR, Koschinsky ML. Analysis of the proteolytic activity of a recombinant form of apolipoprotein(a). Biochemistry. 1995;34:15777-84.
10. van der Hoek YY, Wittekoek ME, Beisiegel U, et al. The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably sized isoforms. Hum Mol Genet. 1993;2:361-6. (Pubitemid 23107209)
11. Lackner C, Cohen JC, Hobbs HH. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet. 1993;2:933-40. (Pubitemid 23216624)
12. Marcovina SM, Hobbs HH, Albers JJ. Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature. Clin Chem. 1996;42:436-9. (Pubitemid 26080932)
13. Marcovina SM, Albers JJ, Wijsman, et al. Differences in Lp(a) concentrations and apo(a) polymorphs between back and white Americans. J Lipid Res. 1996;37:2569-85.
14. Brunner C, Lobentanz EM, Petho-Schramm A, et al. The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells. J Biol Chem. 1996;271:32403-10. (Pubitemid 26422283)
15. Li Y, Luke MM, Shiffman D, Devlin JJ. Genetic variants in the apolipoprotein(a) gene and coronary heart disease. Circ Cardiovasc Genet. 2011;4:565-73.
16. Chennamsetty I, Claudel T, Kostner KM, et al. Farnesoid X receptor represses hepatic human APOA gene expression. J Clin Invest. 2011;121:3724-34.
17. Chennamsetty I, Claudel T, Kostner KM, Trauner M, Kostner GM. FGF19 signaling cascade suppresses APOA gene expression. Arterioscler Thromb Vasc Biol. 2012;32:1220-7.
18. Scanu AM, Bamba R. Nicotinic acid and lipoprotein(a): facts, uncertainties, and clinical considerations. Am J Cardiol. 2008;101:44-7.
19. Chennamsetty I, Kostner KM, Claudel T, et al. Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice. J Lipid Res. 2012;53:2405-12.
20. AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-67.
21. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279-91.
22. Koschinsky ML, Côté GP, Gabel BR, van der Hoek YY. Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100. J Biol Chem. 1993;268:19819-25. (Pubitemid 23270776)
23. Bonen DK, Hausman AM, Hadjiagapiou C, Skarosi SF, Davidson NO. Expression of a recombinant apolipoprotein(a) in HepG2 cells. Evidence for intracellular assembly of lipoprotein(a). J Biol Chem. 1997;272:5659-67. (Pubitemid 27102393)
24. White AL, Lanford RE. Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatocytes. J Biol Chem. 1994;269:28716-23. (Pubitemid 24366708)
25. Becker L, Nesheim ME, Koschinsky ML. Catalysis of covalent Lp(a) assembly: evidence for an extracellular enzyme activity that enhances disulfide bond formation. Biochemistry. 2006;45:9919-28. (Pubitemid 44257437)
26. • Frischmann ME, Ikewaki K, Trenkwalder E, et al. In vivo stable-isotope kinetic study suggests intracellular assembly of lipoprotein(a). Atherosclerosis. 2012;225:322-7. This is a potentially paradigm shifting work that offers a new and different perspective on Lp(a) biosynthesis.
27. Rader DJ, Cain W, Ikewaki K, et al. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest. 1994;93:2758-63.
28. Rader DJ, Mann WA, Cain W, et al. The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest. 1995;95:1403-8.
29. Koschinsky ML, Marcovina SM. Lipoprotein(a). In: Ballantyne CM, editor. Clinical lipidology: a companion to Braunwald's heart disease. Philadelphia: Saunders; 2009. p. 130-43.
30. Takagi H, Umemoto T. Atorvastatin decreases lipoprotein(a): a meta-analysis of randomized trials. Int J Cardiol. 2012;154:183-6.
31. Deshmukh HA, Colhoun HM, Johnson T, et al. Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). J Lipid Res. 2012;53:1000-11.
32. • Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366:1108-18. This is one of a trio of very recent articles identifying novel Lp(a)-lowering strategies.
33. Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade. J Lipid Res. 2012;53:2515-24.
34. Canuel M, Sun X, Asselin MC, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLoS One. 2013;8:e64145.
35. Poirier S, Mayer G, Benjannet S, et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and apoER2. J Biol Chem. 2008;283:2363-72.
36. Konerman M, Kulkarni K, Toth PP, Jones SR. Evidence of dependence of lipoprotein(a) on triglyceride and high-density lipoprotein metabolism. J Clin Lipidol. 2012;6:27-32.
37. Ganji SH, Kamanna VS, Kashyap ML. Niacin and cholesterol: role in cardiovascular disease (review). J Nutr Biochem. 2003;14:298-305. (Pubitemid 36836234)
38. Gurakar A, Hoeg JM, Kostner G, Papadopoulos NM, Brewer Jr HB. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis. 1985;57:293-301. (Pubitemid 16235917)
39. Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol. 2008;101:20B-6B.
40. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844-53.
41. Genest JJ, McNamara JR, Salem DN, Schaefer EJ. Prevalence of risk factors in men with premature coronary heart disease. Am J Cardiol. 1991;67:1185-9.
42. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505-15. (Pubitemid 38477775)
43. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-22. (Pubitemid 350146106)
44. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089-99.
45. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406-15.
46. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA. 2011;306:2099-109.
47. Cao G, Beyer TP, Zhang Y, et al. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J Lipid Res. 2011;52:2169-76.
48. • Visser ME, Witztum JL, Stroes ES, Kastelein JJ. Antisense oligonucleotides for the treatment of dyslipidemia. Eur Heart J. 2012;33:1451-8. This is one of a trio of recent articles identifying novel Lp(a)-lowering strategies.
49. Jaeger BR, Richter Y, Nagel D, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med. 2009;6:229-39.
50. • Safarova MS, Ezhov MV, Afanasieva OI, et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler Suppl. 2013;14:93-9. This is one of a trio of recent articles identifying novel Lp(a)-lowering strategies.
51. Boerwinkle E, Leffert CC, Lin J, et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1990;90:52-60.
52. Sandholzer C, Boerwinkle E, Saha N, et al. Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease. J Clin Invest. 1992;89:1040-6.
53. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518-28.
54. Koch W, Mueller JC, Schrempf M, et al. Two rare variants explain association with acute myocardial infarction in an extended genomic region including the apolipoprotein(A) gene. Ann Hum Genet. 2013;77:47-55.
55. Lv X, Zhang Y, Rao S, et al. Lack of association between four SNPs in the SLC22A3-LPAL2-LPA gene cluster and coronary artery disease in a Chinese Han population: a case control study. Lipids Health Dis. 2012;11:128.
56. Chasman DI, Shiffman D, Zee RY, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis. 2009;203:371-6.
57. Shiffman D, Slawsky K, Fusfeld L, Devlin JJ, Goss TF. Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease. Clin Ther. 2012;34:1387-94.
58. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331-9.
59. Kronenberg F, Kronenberg MF, Kiechl S, et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation. 1999;100:1154-60. (Pubitemid 29426589)
60. Paultre F, Pearson TA, Weil HF, et al. High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and White men. Arterioscler Thromb Vasc Biol. 2000;20:2619-24.
61. Erqou S, Thrompson A, Di Angelantonio E, et al. Apolipoprotein(a) isoforms and the risk of vascular disease. J Am Coll Cardiol. 2010;55:2160-7.
62. Enkhmaa B, Anuurad E, Zhang W, Tran T, Berglund L. Lipoprotein(a): genotype-phenotype relationship and impact on atherogenic risk. Metab Syndr Relat Disord. 2011;9:411-8.
63. Gurdasani D, Sjouke B, Tsimikas S, et al. Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol. 2012;32:3058-65.
64. Goldenberg NA, Bernard TJ, Hillhouse J, et al. Elevated lipoprotein (a), small apolipoprotein (a), and the risk of arterial ischemic stroke in North American children. Haematologica. 2013;98:802-7.
65. Ronald J, Rajagopalan R, Cerrato F, et al. Genetic variation in LPAL2, LPA, and PLG predicts plasma lipoprotein(a) level and carotid artery disease risk. Stroke. 2011;42:2-9.
66. Momiyama Y, Ohmori R, Fayad ZA, et al. Associations between serum lipoprotein(a) levels and the severity of coronary and aortic atherosclerosis. Atherosclerosis. 2012;222:241-4.
67. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem. 2003;49:1785-96. (Pubitemid 37340313)
68. Brown WV, Ballantyne CM, Jones PH, Marcovina S. Management of Lp(a). J Clin Lipidol. 2010;4:240-7.
69. • Davidson MH, Ballantyne CM, Jacobson TA, et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol. 2011;5:338-67. This is a comprehensive work that offers evidence-based advice on the use of Lp(a) in the clinical setting.
70. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2001;104:1108-13. (Pubitemid 32830392)
71. Emerging Risk Factors Collaboration. Lipid-related markers and cardiovascular disease prediction. JAMA. 2012;307:2499-506.
72. Robinson JG. What is the role of advanced lipoprotein analysis in practice? J Am Coll Cardiol. 2012;60:2607-15.
73. Boffa MB, Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem. 2004;37:333-43. (Pubitemid 38490450)
74. Aznar J, Estellés A, Bretó M, España F, Alós T. Euglobulin clot lysis induced by tissue-type plasminogen activator is reduced in subjects with increased levels of lipoprotein (a). Thromb Res. 1992;66:569-82.
75. • Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis. Arterioscler Thromb Vasc Biol. 2012;32:1732-41. This is one of two recent articles that suggest the primary pathogenic mechanism of Lp(a) is promotion of atherosclerosis, not inhibition of fibrinolysis.
76. • Helgadottir A, Gretarsdottir S, Thorleifsson G, et al. Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol. 2012;60:722-9. This is one of two recent articles that suggest the primary pathogenic mechanism of Lp(a) is promotion of atherosclerosis, not inhibition of fibrinolysis.
77. Bergmark C, Dewan A, Orsoni A, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res. 2008;49:2230-9.
78. Tsimikas S, Clopton P, Brilakis ES, et al. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation. 2009;119:1711-9.
79. Edelstein C, Pfaffinger D, Hinman J, et al. Lysine-physphatidylcholine adducts in kringle V impart unique immunological and protein pro-inflammatory properties to human apolipoprotein(a). J Biol Chem. 2003;278:52841-7. (Pubitemid 38035883)
80. Kiechl S, Willeit J, Mayr M, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol. 2007;27:1788-95. (Pubitemid 47207175)
81. Tsimikas S, Mallat Z, Talmud PJ, et al. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol. 2010;56:946-55.
82. Seimon TA, Nadolski MJ, Liao X, et al. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab. 2010;12:467-82.
83. • van Dijk RA, Kolodgie F, Ravandi A, et al. Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J Lipid Res. 2012;53:2773-90. This is a richly detailed work that links apo(a) and oxidized phospholipids to dangerous developments in advanced atherosclerotic lesions.
84. Qasim AN, Martin SS, Mehta NN, et al. Lipoprotein(a) is strongly associated with coronary artery calcification in type-2 diabetic women. Int J Cardiol. 2011;150:17-21.
85. Raggi P, Cooil B, Hadi A, Friede G. Predictors of aortic and coronary artery calcium on a screening electron beam tomographic scan. Am J Cardiol. 2003;91:744-6. (Pubitemid 36287475)
86. Lee TC, O'Malley PG, Feuerstein I, Taylor AJ. The prevalence and severity of coronary artery calcification on coronary artery computed tomography in black and white subjects. J Am Coll Cardiol. 2003;41:39-44. (Pubitemid 36044401)
87. Guerra R, Yu Z, Marcovina S, Peshock R, Cohen JC, Hobbs HH. Lipoprotein(a) and apolipoprotein(a) isoforms: no association with coronary artery calcification in the Dallas Heart Study. Circulation. 2005;111:1471-9. (Pubitemid 40470640)
88. Kullo IJ, Bailey KR, Bielak LF, et al. Lack of association between lipoprotein(a) and coronary artery calcification in the Genetic Epidemiology Network of Arteriopathy (GENOA) study. Mayo Clin Proc. 2004;79:1258-63. (Pubitemid 39299069)
89. Sun H, Unoki H, Wang X, et al. Lipoprotein(a) enhances advanced atherosclerosis and vascular calcification in WHHL transgenic rabbits expressing human apolipoprotein(a). J Biol Chem. 2002;277:47486-92. (Pubitemid 36159266)
90. Jug B, Papazian J, Lee R, Budoff MJ. Association of lipoprotein subfractions and coronary artery calcium in patient at intermediate cardiovascular risk. Am J Cardiol. 2013;111:213-8.
91. Greif M, Arnoldt T, von Ziegler F, et al. Lipoprotein (a) is independently correlated with coronary artery calcification. Eur J Intern Med. 2013;24:75-9.
92. • Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368:503-12. This very recent work unexpectedly implicates Lp(a) in the development of calcification in nonatherosclerotic aortic valvular disease.